These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28972441)

  • 1. Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs.
    Kobayashi D; Ito S; Takai C; Hasegawa E; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Mod Rheumatol; 2018 Jul; 28(4):599-605. PubMed ID: 28972441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.
    Takeuchi T; Yamanaka H; Tanaka Y; Sakurai T; Saito K; Ohtsubo H; Lee SJ; Nambu Y
    Mod Rheumatol; 2015; 25(6):817-24. PubMed ID: 25736355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.
    Takai C; Ito S; Kobayashi D; Nemoto T; Lee H; Abe A; Otani H; Nakazono K; Murasawa A; Ishikawa H
    Intern Med; 2020; 59(16):1963-1970. PubMed ID: 32801270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events.
    Wakabayashi H; Inada H; Nishioka Y; Hasegawa M; Nishioka K; Sudo A
    Drugs R D; 2017 Mar; 17(1):233-239. PubMed ID: 28025727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
    Costa Jde O; Lemos LL; Machado MA; Almeida AM; Kakehasi AM; Araújo Vde E; Cherchiglia ML; Andrade EI; Acurcio Fde A
    Rev Bras Reumatol; 2015; 55(2):146-58. PubMed ID: 25593074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.
    Alten R; Batko B; Hala T; Kameda H; Radominski SC; Tseluyko V; Babic G; Cronenberger C; Hackley S; Rehman M; von Richter O; Zhang M; Cohen S
    RMD Open; 2019; 5(1):e000876. PubMed ID: 30997153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study).
    Nam JL; Villeneuve E; Hensor EM; Conaghan PG; Keen HI; Buch MH; Gough AK; Green MJ; Helliwell PS; Keenan AM; Morgan AW; Quinn M; Reece R; van der Heijde DM; Wakefield RJ; Emery P
    Ann Rheum Dis; 2014 Jan; 73(1):75-85. PubMed ID: 23912798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Study of Infliximab Therapy and Methotrexate Monotherapy to Improve the Clinical Effect in Rheumatoid Arthritis Patients.
    Miwa Y; Isojima S; Saito M; Ikari Y; Kobuna M; Hayashi T; Takahashi R; Kasama T; Hosaka M; Sanada K
    Intern Med; 2016; 55(18):2581-5. PubMed ID: 27629950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
    van der Kooij SM; le Cessie S; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; van Zeben D; Kerstens PJ; Hazes JM; van Schaardenburg D; Breedveld FC; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2009 Jul; 68(7):1153-8. PubMed ID: 18930988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
    Kurasawa T; Nagasawa H; Kishimoto M; Amano K; Takeuchi T; Kameda H
    Mod Rheumatol; 2014 Jul; 24(4):561-6. PubMed ID: 24252035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
    Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
    Cohen SB; Radominski SC; Kameda H; Kivitz AJ; Tee M; Cronenberger C; Zhang M; Hackley S; Rehman MI; von Richter O; Alten R
    BioDrugs; 2020 Apr; 34(2):197-207. PubMed ID: 31939063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis.
    Takasugi K; Nishida K; Natsumeda M; Yamashita M; Yamamoto W; Ezawa K
    Mod Rheumatol; 2018 May; 28(3):452-460. PubMed ID: 28828944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study.
    Lila AM; Mazurov VI; Denisov LN; Nesmeyanova OB; Ilivanova EP; Eremeeva AV; Usacheva JV; Dokukina EA; Chernyaeva EV; Ivanov RA
    Rheumatol Int; 2019 Sep; 39(9):1537-1546. PubMed ID: 31292709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study.
    Nakamura S; Suzuki K; Iijima H; Hata Y; Lim CR; Ishizawa Y; Kameda H; Amano K; Matsubara K; Matoba R; Takeuchi T
    Arthritis Res Ther; 2016 Jul; 18():159. PubMed ID: 27435242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of clinical response after 1 year of infliximab therapy in rheumatoid arthritis based on disease activity at 3 months: posthoc analysis of the RISING study.
    Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
    J Rheumatol; 2015 Apr; 42(4):599-607. PubMed ID: 25684765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.
    Kameda H; Uechi E; Atsumi T; Abud-Mendoza C; Kamei K; Matsumoto T; Ponce de Leon D; Rehman MI; Zhang M; Radominski SC
    Int J Rheum Dis; 2020 Jul; 23(7):876-881. PubMed ID: 32476277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.
    Kawashiri SY; Shimizu T; Sato S; Morimoto S; Kawazoe Y; Sumiyoshi R; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Jul; 99(30):e21151. PubMed ID: 32791688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist.
    Bao J; Yue T; Li T; He DY; Bao YX
    Int J Rheum Dis; 2016 Apr; 19(4):370-6. PubMed ID: 24798350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis.
    Pérez-Guijo VC; Cravo AR; Castro Mdel C; Font P; Muñoz-Gomariz E; Collantes-Estevez E
    Joint Bone Spine; 2007 May; 74(3):254-8. PubMed ID: 17387031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.